BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent’s candidates hold great promise for the future of immuno-oncology.

Read the article at biostock.se:

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0” - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Bioinvent

Läses av andra just nu

Om aktien Bioinvent

Senaste nytt